DOP Session 8

  • 17:20-18:20 Digital Oral Presentation Session 8 - Treatment strategies
    Room: Stolz 1-2, Ground Floor, Congress Centre
    Chairs:
    Antonio López-Sanromán, Madrid, Spain
    Christian Maaser, Luneburg, Germany
      17:20-17:26 DOP064: ECCO Expert Consensus and topical review on Treatment Exit Strategies in Inflammatory Bowel Disease
    G. Doherty1, K. Katsanos2, J. Burisch3, M. Allez4, K. Papamichael5, A. Stallmach6, R. Mao7, I. Prytz Berset8, J. Gisbert9, S. Sebastian10, J. Kierkuś11, L. Lopetuso12, E. Szymanska11, E. Louis13
    1. St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland
    2. University and Medical School of Ioannina, Ioannina, Greece
    3. North Zealand University Hospital, Frederikssund, Denmark
    4. Hôpital Saint-Louis, APHP, INSERM UMRS 1160, Université Denis Diderot, Paris, France
    5. Beth Israel Deaconess Medical Center, Department of Gastroenterology, Boston, United States
    6. University Hospital Jena, Department of Medicine, Jena, Germany
    7. The First Affiliated Hospital Of Sun Yat-sen University, Guangzhou, China
    8. alesund Hospital, Department of Gastroenterology, Alesund, Norway
    9. Hospital Universitario de La Princesa, Department of Gastroenterology, Madrid, Spain
    10. Hull & East Yorkshire NHS Trust, Hull & York Medical School, Hull, United Kingdom
    11. Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Warsaw, Poland
    12. Catholic University of Rome - A. Gemelli Hospital, Department of Internal Medicine and Gastroenterology, Rome, Italy
    13. CHU Liege, Sart Tilman, Department of Pediatric Gastroenterology, Liege, Belgium
      17:26-17:32 DOP065: Long term cost effectiveness of tight control for Crohn’s Disease with adalimumab-based treatment: Economic evaluation beyond 48 weeks of CALM trial
    R. Panaccione1, J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, S. Johnson9, M. Buessing9, E. Neimark10, J. Petersson10, A.M. Robinson10, R.B. Thakkar10, W.-J. Lee10, M. Skup10, G. D’Haens11
    1. University of Calgary, Calgary, Canada
    2. Icahn School of Medicine atMount Sinai, New York, United States
    3. Imelda General Hospital, Bonheiden, Belgium
    4. AZ Delta Roeselare-Menen, Roeselare-Menen, Belgium
    5. Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czech Republic
    6. Bezmialem Vakif University, Istanbul, Turkey
    7. Medical University of Vienna, Vienna, Austria
    8. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy
    9. Medicus Economics LLC, Boston, United States
    10. AbbVie Inc., North Chicago, United States
    11. IBD Unit, Academic Medical Center, Amsterdam, Netherlands
      17:32-17:38 DOP066: Developing a Core Outcome Set for Fistulising Perianal Crohn’s Disease
    K. Sahnan, P.J. Tozer1, S.O. Adegbola1, M.J. Lee2, N. Heywood3, A.G.K. McNair4, D. Hind5, N. Yassin6, A.J. Lobo7, S.R. Brown2, S. Sebastian8, R.K. Phillips1, P.F. Lung9, O.D. Faiz1, K. Crook10, S. Blackwell11, A. Verjee12, A.L. Hart13, N.S. Fearnhead14
    1. St Mark's Hospital, Colorectal Surgery, London, United Kingdom
    2. Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Department of Colorectal Surgery, Sheffield, United Kingdom
    3. University Hospital South Manchester, Department of Colorectal Surgery, Manchester, United Kingdom
    4. Bristol, School of Social and Community Medicine, Bristol, United Kingdom
    5. Clinical Trials Research Unit, School of Health and Related Research, Sheffield, UK, Sheffiled, United Kingdom
    6. Birmingham University Hospitals NHS Trust, Birmingham, United Kingdom
    7. Sheffield Teaching Hospitals NHS Trust, Northern General Hospital, Department of Gastroenterology, Sheffield, United Kingdom
    8. Hull Royal Infirmary, Hull & East Yorkshire Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Hull, United Kingdom
    9. St Mark's Hospital, Gastrointestinal Imaging, London, United Kingdom
    10. St Mark's Hospital, Department of IBD, London, United Kingdom
    11. Patient representative, Liverpool, United Kingdom
    12. Patient representative, London, United Kingdom
    13. St Mark's Hospital, IBD/Physiology, London, United Kingdom
    14. Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Colorectal Surgery, Cambridge, United Kingdom
      17:38-17:44 DOP067: Treatment discontinuation, flares and hospitalisations among biologic-naïve patients with IBD over the first year of treatment: A comparative effectiveness study of vedolizumab versus infliximab
    M. Raluy-Callado1, A. Berger2, J.M. Khalid3H. Patel3
    1. Evidera, Real-World Evidence, London, United Kingdom
    2. Evidera, Real World Evidence, Waltham, MA, United States
    3. Takeda Development Centre Europe Ltd, Evidence and Value Generation, London, United Kingdom
      17:44-17:50 DOP068: Crohn’s Disease decision aid leads to more patients choosing combination therapy in a cluster randomised controlled trial
    C.A. Siegel1, K.D. Thompson1, L.S. Siegel2, T. MacKenzie3, M.C. Dubinsky4
    1. Dartmouth-Hitchcock Medical Center, Lebanon, United States
    2. Climate Interactive, Hanover, United States
    3. Geisel School of Medicine at Dartmouth, Hanover, United States
    4. Icahn School of Medicine at Mount Sinai, New York, United States
      17:50-17:56 DOP069: Improved quality of care & quality of life for IBD patients using mobile based remote monitoring platform: A randomised control trial
    A. Atreya1, E. Otobo1, E. Szigethy2, H. Shroff1, H. Chang1, L. Keefer1, J. Rogers1, T. Ullman1, J.F. Marion1, B. Cohen1, E. Maser1, S. Itzkowitz1, J.-F. Colombel1, B. Sands1
    1. Icahn School of Medicine at Mount Sinai, New York, United States
    2. University of Pittsburgh, Pittsburgh, United States
       17:56-18:02 DOP070: Development and pilot of an index to identify young people with Inflammatory Bowel Disease at risk of psychological morbidity
    R.T. Lees1, A.J. Brooks1, G. Rowse2, P. Narula3, P. Norman4, A.J. Lobo1
    1. Sheffield Teaching Hospitals, Department of Gastroenterology, Sheffield, United Kingdom
    2. University of Sheffield, Clinical Psychology Unit, Sheffield, United Kingdom
    3. Sheffield Children’s Hospital, Gastroenterology Department, Sheffield, United Kingdom
    4. University of Sheffield, Department of Psychology, Sheffield, United Kingdom
      18:02-18:08 DOP071: Tight control with adalimumab-based treatment is associated with improved quality of life outcomes in patients with moderate to severely active Crohn's Disease: Data from CALM
    R. Panaccione1 , J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, E. Neimark9, J. Petersson9, A.M. Robinson9, R.B. Thakkar9, N. Chen9, M. Skup9, W.-J. Lee9, G. D’Haens10
    1. University of Calgary, Calgary, Canada
    2. Icahn School of Medicine at Mount Sinai, New York, United States
    3. Imelda General Hospital, Bonheiden, Belgium
    4. AZ Delta Roeselare-Menen, Roeselare-Menen, Belgium
    5. Hepato-Gastroenterologie HK, s.r.o., Hradec Králové, Czech Republic
    6. Bezmialem Vakif University, Istanbul, Turkey
    7. Medical University of Vienna, Vienna, Austria
    8. Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy
    9. AbbVie Inc., North Chicago, United States
    10. IBD Unit, Academic Medical Center, Amsterdam, Netherlands
      18:08-18:14 DOP072: Achieving biochemical remission with adalimumab therapy using therapeutic drug monitoring: Results of a large prospective Crohn’s Disease cohort
    N. Plevris, P. Jenkinson, C.S. Chuah, M. Lyons, R. Hall, G. Jones, E. Watson, I. Arnott, C. Lees
    NHS Lothian, Gastroenterology, Edinburgh, United Kingdom